

Psychedelics Won't Save Psychiatry — Yet

But their rollout could make or break mental health innovation.

Swipe for insights →

THE DATA

Clinically meaningful response rate

In Compass Pathways' Phase 3 trials, roughly a quarter of patients showed improvement after a single dose of COMP360.

It's not a cure, but it signals a potential shift from chronic, incremental treatment to rapid, transformative intervention. The data suggest that a single supervised session can yield measurable change where traditional antidepressants often fail.

Source: STAT News • Published October 14, 2026

https://www.statnews.com/2026/10/14/compass-pathways-psychedelics-stat-summit/?utm_campaign=RSS



01

Blinding Is Broken by Design



The implication for AI in healthcare: machine learning models trained on traditional, blinded trial data may mispredict outcomes for psychedelic therapies unless they are retrained on unblinded, experience-weighted datasets.



02

Speed Kills Credibility

For AI in healthcare, this means that predictive models for drug safety must be trained not just on clinical trial data, but on real-world post-approval signals — and must be able to flag deviations from expected outcomes before they become systemic.

MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy.
Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member.
Associate Broker.

George Arnold Alexander III, MPA

Director, ALEX Companies

Associate Broker, Alexander Tiffany Southwest, LLC dba ALEX.realestate, et.al.

Texas License #574878-B · Broker License #565194-BB

Broker, ALEX Real Estate · North Carolina License #367733

Independent Broker, ALEX Real Estate · Colorado License #II.100112456

george@alex.realestate · +1 713.918.9951



ALEX Intelligence
deep intelligence

ALEX Real Estate
genius real estate

ALEX Advisory
uncontested strategy

ALEX Cares
purposeful philanthropy

